BioNTech SE's RNA-based vaccine for malaria placed on clinical hold by FDA
BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...
BioNTech stock falls after FDA clinical hold on malaria vaccine trial
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
Study finds new potential for prostate cancer immunotherapy
A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ...
How AI Could Revolutionize Drug Development and Save Billions
BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...
WebMD8h
FDA Approves New Treatment for Stroke
The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.
clinicaladvisor.com10h
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).
Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment
Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
manilatimes13h
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...
precisionmedicineonline1d
Avirmax Biopharma Targeting FDA IND Application Submission for Dry AMD Gene Therapy Later This Year
ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.